



October 15, 2020

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir(s),

Subject: Launch of Acalabrutinib 100mg capsules (Calquence®)

We refer to our earlier communication dated March 12, 2020 intimating the receipt of Import and Market Permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Acalabrutinib 100mg capsules (**Calquence®**).

With regard to the same, we now wish to further update that AstraZeneca Pharma India Limited will launch **Calquence®** in India on October 21, 2020.

Acalabrutinib 100mg capsules (**Calquence®**) is:

- indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
- indicated for treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL).

We request you to kindly take the above same on records.

Thanking You,

For **AstraZeneca Pharma India Limited**

Pratap Rudra

Company Secretary & Legal Counsel

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkata, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628